Target Discovery Scientist: Patient-Driven Genomics

Overview

By uniquely bringing Patient Selection into the Target Identification stage.

Approach

Using real patients data, we integrate target identification with cohort selection into a single coherent strategy.

We use 100% of Genome Data, both Exome & Dark Genome alterations. With a wealth of patient-derived tumor data, we can identify novel drug targets “invisible” in cell line-based assays.

Gordion Bioscience Inc., 245 Main St, Cambridge, MA 02142, US

#J-18808-Ljbffr